Biotech entity
All 2 tracked stories fall under one category: pharma. Takeda Pharmaceutical is most often covered alongside CSL Behring, which appears in 1 of these 2 stories. Across a 26-day span, the pace is roughly 0.5 stories per week. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Takeda Pharmaceutical is most often covered alongside CSL Behring, which appears in 1 of these 2 stories. Across a 26-day span, the pace is roughly 0.5 stories per week. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. At 5.5, the average consequence score sits below the same-window beat average of 6. Takeda Pharmaceutical appears in 2 tracked Biotech stories published from February 20, 2026 through March 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 297 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Takeda Pharmaceutical. Shared-story counts are live from our verified record — not editorial picks.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by massive investments in plasma collection infrastructure and rising demand for primary immunodeficiency treatments. This growth reflects a stabilization of the supply chain following pandemic-era disruptions and a strategic shift toward subcutaneous delivery methods.
Takeda Pharmaceutical is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
